Ten to twenty percent of patients diagnosed with breast cancer are diagnosed with triple-negative breast cancer (ER-, PR-, Her2-; TNBC) for which the 5-year survival rate is only < 30% [2, 3]. This evidence concerns the gene ERBB2 and breast carcinoma.